Literature DB >> 33567877

Glycemic Variability Assessment with a 14-Day Continuous Glucose Monitoring System: When and How Long to Measure MAGE (Mean Amplitude of Glucose Excursion) for Optimal Reliability?

Bruno Vergès1,2, Elise Pignol1, Alexia Rouland1,2, Benjamin Bouillet1,2, Sabine Baillot-Rudoni1, Emilienne Quilot3, Abdelmadjid Djeffal3, Jean Michel Petit1,2.   

Abstract

Mean amplitude of glucose excursion (MAGE) is considered as the "gold standard" for assessing the short-term within-day glycemic variability (GV), which is an important component of overall glycemic control. A 14-day continuous glucose monitoring system is now widely used and allows easier assessment of GV. However, it is still unknown whether MAGE, usually calculated on a 48-hour period is identical whatever the time during the 14-day lifespan of the sensor and whether a longer time period might give additional information. We evaluated in 68 patients with type 1 diabetes, MAGE during three 2-day periods (day1-day3; day6-day8; day11-day13) and during periods of 3 days and 4 days. MAGE calculated at the three 2-day periods were identical and not different from MAGE of the 3-day or 4-day periods.

Entities:  

Keywords:  MAGE; continuous glucose monitoring; freestyle libre; glycemic variability; type 1 diabetes

Mesh:

Substances:

Year:  2021        PMID: 33567877      PMCID: PMC9264451          DOI: 10.1177/1932296821992060

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  15 in total

1.  Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control.

Authors:  Jan Šoupal; Jan Škrha; Martin Fajmon; Eva Horová; Miloš Mráz; Jan Škrha; Martin Prázný
Journal:  Diabetes Technol Ther       Date:  2014-01-08       Impact factor: 6.118

2.  Glycaemic variability is associated with severity of coronary artery disease in patients with poorly controlled type 2 diabetes and acute myocardial infarction.

Authors:  M Benalia; M Zeller; B Mouhat; C Guenancia; V Yameogo; C Greco; H Yao; M Maza; B Vergès; Y Cottin
Journal:  Diabetes Metab       Date:  2019-02-11       Impact factor: 6.041

Review 3.  Glycemic Variability: Risk Factors, Assessment, and Control.

Authors:  Boris Kovatchev
Journal:  J Diabetes Sci Technol       Date:  2019-01-29

4.  Glycaemic variability using continuous glucose monitoring and endothelial function in the metabolic syndrome and in Type 2 diabetes.

Authors:  S Buscemi; A Re; J A Batsis; M Arnone; A Mattina; G Cerasola; S Verga
Journal:  Diabet Med       Date:  2010-08       Impact factor: 4.359

5.  Glycemic Variability Is a Powerful Independent Predictive Factor of Midterm Major Adverse Cardiac Events in Patients With Diabetes With Acute Coronary Syndrome.

Authors:  Edouard Gerbaud; Romain Darier; Michel Montaudon; Marie-Christine Beauvieux; Christine Coffin-Boutreux; Pierre Coste; Hervé Douard; Alexandre Ouattara; Bogdan Catargi
Journal:  Diabetes Care       Date:  2019-02-06       Impact factor: 19.112

6.  Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.

Authors:  Roy W Beck; Richard M Bergenstal; Tonya D Riddlesworth; Craig Kollman; Zhaomian Li; Adam S Brown; Kelly L Close
Journal:  Diabetes Care       Date:  2018-10-23       Impact factor: 19.112

Review 7.  The application of simple metrics in the assessment of glycaemic variability.

Authors:  L Monnier; C Colette; D R Owens
Journal:  Diabetes Metab       Date:  2018-03-06       Impact factor: 6.041

8.  Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes.

Authors:  Gong Su; Shuhua Mi; Hong Tao; Zhao Li; Hongxia Yang; Hong Zheng; Yun Zhou; Changsheng Ma
Journal:  Cardiovasc Diabetol       Date:  2011-02-25       Impact factor: 9.951

9.  Nerve conduction study of the association between glycemic variability and diabetes neuropathy.

Authors:  Miho Akaza; Itaru Akaza; Tadashi Kanouchi; Tetsuo Sasano; Yuki Sumi; Takanori Yokota
Journal:  Diabetol Metab Syndr       Date:  2018-09-12       Impact factor: 3.320

10.  Glycemic Variability and Its Impact on Quality of Life in Adults With Type 1 Diabetes.

Authors:  Monika Reddy; Ian F Godsland; Katharine D Barnard; Pau Herrero; Pantelis Georgiou; Hazel Thomson; Desmond G Johnston; Nick S Oliver
Journal:  J Diabetes Sci Technol       Date:  2015-08-18
View more
  1 in total

1.  Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.

Authors:  Shangyu Chai; Ruya Zhang; Ye Zhang; Richard David Carr; Yiman Zheng; Swapnil Rajpathak; Miao Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-09       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.